These apCAFs subsequently recruit FOXP1+ regulatory T cells through PD-L2-RGMB interactions, contributing to neoadjuvant immunotherapy resistance in early-stage lung cancer [64]. The gene discussed is FOXP1; the disease is lung cancer.